Home » Newsletters » BioWorld Science

BioWorld Science

April 20, 2009

View Archived Issues

Novel Janus kinase 2 inhibitors disclosed by Merck & Co.

AstraZeneca claims novel phthalazinone derivatives for cancer treatment

GSK reports novel glycine transporter inhibitors for schizophrenia treatment

Muscarinic M3 antagonists described by Pfizer for the treatment of COPD and asthma

Bayer claims novel compounds for the treatment of dyslipidemia

Biomarker identified for response to tipifarnib-bortezomib in acute myeloid leukemia

Saracatinib monotherapy shows little efficacy in advanced, castration-resistant prostate cancer

Novimmune designs antibodies with multiple specificities

Johnson & Johnson reviews first quarter 2009

Dainippon discontinues development of AC-3933 for dementia

Gilead begins phase II trial for integrase-based, single-tablet, once-daily HIV treatment

VentiRx initiates phase I VTX-1463 trial in allergic rhinitis

Galapagos and Merck to develop small-molecule drugs in inflammatory diseases

Preliminary results from ongoing phase I MDX-1401 trial in Hodgkin lymphoma patients reported

Multivalent, virosome-based breast cancer vaccine deemed safe, well tolerated in phase I trial

Pregabalin may be beneficial in patients with chronic hepatitis C

Advaxis initiates drug-licensing discussions in non-U.S. markets for ADXS11-001

PAION initiates phase Ib study of CNS-7056 in volunteers undergoing colonoscopy

Pharmacyclics and Servier enter global strategic alliance for PCI-24781

Adeona to acquire Colwell Clinical Laboratories

Amarillo supplies oral interferon for Australian human influenza study

Osiris completes enrollment in phase III Prochymal trial for graft vs. host disease

The European Commission withdraws marketing authorization for Velosulin

Gilead acquires CV Therapeutics

Factor VIIa inhibitors presented by Eisai for the treatment of thrombotic disorders

Popular Stories

Today's news in brief
BioWorld
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
Keros reports beneficial effects of RKER-065 in ALS model
BioWorld Science
Keros Therapeutics Inc. has presented data regarding their activin receptor ligand trap, RKER-065, for the inhibition of the activin/myostatin signaling axis.
News in brief
BioWorld Asia
BioWorld Asia briefs for March 17, 2026
First-in-class POLG activator restores mtDNA across mutations
BioWorld Science
Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...